Chataway J - Search Results

1

Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis.

Vesterinen HM, Connick P, Irvine CM, Sena ES, Egan KJ, Carmichael GG, Tariq A, Pavitt S, Chataway J, Macleod MR, Chandran S. Vesterinen HM, et al. Among authors: chataway j. PLoS One. 2015 Apr 9;10(4):e0117705. doi: 10.1371/journal.pone.0117705. eCollection 2015. PLoS One. 2015. PMID: 25856304 Free PMC article.

2

Multiple sclerosis.

Nicholas R, Chataway J. Nicholas R, et al. Among authors: chataway j. BMJ Clin Evid. 2007 Aug 15;2007:1202. BMJ Clin Evid. 2007. PMID: 19454107 Review.

3

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.

Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdés-Márquez E, Stallard N, Friede T. Chataway J, et al. Mult Scler. 2011 Jan;17(1):81-8. doi: 10.1177/1352458510382129. Epub 2010 Aug 26. Mult Scler. 2011. PMID: 20798135

4

Natalizumab therapy for multiple sclerosis.

Chataway J, Miller DH. Chataway J, et al. Neurotherapeutics. 2013 Jan;10(1):19-28. doi: 10.1007/s13311-012-0171-4. Neurotherapeutics. 2013. PMID: 23307290 Free PMC article. Review.

5

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Ontaneda D, Fox RJ, Chataway J. Ontaneda D, et al. Among authors: chataway j. Lancet Neurol. 2015 Feb;14(2):208-23. doi: 10.1016/S1474-4422(14)70264-9. Lancet Neurol. 2015. PMID: 25772899 Free PMC article. Review.

6

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K. Pakpoor J, et al. Among authors: chataway j. Neurol Neuroimmunol Neuroinflamm. 2015 Oct 1;2(6):e158. doi: 10.1212/NXI.0000000000000158. eCollection 2015 Dec. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26468472 Free PMC article.

7

Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Plantone D, De Angelis F, Doshi A, Chataway J. Plantone D, et al. Among authors: chataway j. CNS Drugs. 2016 Jun;30(6):517-26. doi: 10.1007/s40263-016-0340-9. CNS Drugs. 2016. PMID: 27166830 Review.

8

Multiple sclerosis, a treatable disease.

Doshi A, Chataway J. Doshi A, et al. Among authors: chataway j. Clin Med (Lond). 2016 Dec;16(Suppl 6):s53-s59. doi: 10.7861/clinmedicine.16-6-s53. Clin Med (Lond). 2016. PMID: 27956442 Free PMC article. Review.

9

Advancing trial design in progressive multiple sclerosis.

Fox RJ, Chataway J. Fox RJ, et al. Among authors: chataway j. Mult Scler. 2017 Oct;23(12):1573-1578. doi: 10.1177/1352458517729768. Mult Scler. 2017. PMID: 29041871 Free PMC article.

10

A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.

Webb EJD, Meads D, Eskyte I, King N, Dracup N, Chataway J, Ford HL, Marti J, Pavitt SH, Schmierer K, Manzano A. Webb EJD, et al. Among authors: chataway j. Patient. 2018 Aug;11(4):391-402. doi: 10.1007/s40271-017-0296-y. Patient. 2018. PMID: 29313265 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters